

July 25, 2025

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai-400 001  
**Scrip Code-540025**

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (E) Mumbai-400 051  
**Trading Symbol-ADVENZYMES**

Dear Sir/Madam,

**Subject: Intimation of an Investment proposal approved by the Board of Directors of a subsidiary, JC Biotech Private Limited - Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Ref: ISIN: INE837H01020**

This is to inform that the Board of Directors of JC Biotech Private Limited ("95.72% Subsidiary") at its Meeting held on July 25, 2025, has approved a collaboration of the Subsidiary with Raywatt Solar Power Systems Private Limited ("Developer") engaged in the development of group captive Solar power project, to avail the power / electricity requirement through solar for the said Subsidiary's Plant located at APIIC Growth centre, Gundlapalli Village, Ongole, Andhra Pradesh.

The Developer would undertake the group captive solar power plant project through a Special Purpose Vehicle company ("SPV") wherein the buyer of the solar power is required to invest in at least 26% of the said SPV as per the requirement of the applicable laws. In view of this, the said Subsidiary will be required to invest in 26% Equity shares of such SPV.

The relevant details as required under the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 are enclosed as Annexure - A.

The above information is also made available on the website of the Company at <https://www.advancedenzymes.com/investors/stock-exchange-compliance/#other-compliance>

This is for your information and for public at large.

Thanking you,

Yours faithfully,

**For Advanced Enzyme Technologies Limited**

Sanjay Basantani

Company Secretary and Head – Legal

Encl.: As above

**Annexure - A**

Name of the target entity, details in brief such as size, turnover etc	<p>JC Biotech Private Limited (95.72% Subsidiary) in its Board Meeting held today accorded its approval to collaborate with Raywatt Solar Power Systems Private Limited ("Developer") who is engaged in the development of group captive solar power plant project. In such projects, the Developer undertakes group captive solar power project through a Special Purpose Vehicle company incorporated in India ("SPV"), wherein the buyer of solar power is required to hold atleast 26% equity stake as per the applicable provisions. Hence, the said Subsidiary will be required to invest in 26% Equity Shares of a SPV ("Target Entity") and collaborate with such Developer. The Board of JC Biotech Private Limited, Subsidiary, approved investment in / acquisition of 26% of the Target Entity/SPV to be incorporated in India.</p> <p>Turnover, Profit After Tax: Not Applicable as of now as the Target Entity/SPV is yet to be incorporated / finalized with the developer.</p>
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	Not Applicable
Industry to which the entity being acquired belongs	Special Purpose Vehicle - for generation of Solar Power, Group Captive solar power plant Project
Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	The aforesaid Subsidiary to collaborate with the Developer for setting up a solar power plant through its Special Purpose Vehicle (Target Entity) to meet the power / electricity requirements through solar for the Plant of the Subsidiary located at APIIC Growth centre, Gundlapalli Village, Ongole, Andhra Pradesh, through a sustainable source (solar) and in a cost effective manner from a long term perspective.
Brief details of any governmental or regulatory approvals required for the acquisition	No such governmental or regulatory approval is required by the Subsidiary for the said amount of investment
Indicative time period for completion of the acquisition	March 31, 2026

**Advanced Enzyme Technologies Ltd.**

CIN: L24200MH1989PLC051018

Sun Magnetica, 'A' wing, 5th Floor, LIC Service Road, LouiSwadi, Thane (W)-400 604, India

Tel: +91-22-4170 3200, Fax: +91-22-2583 5159

Email: [info@advancedenzymes.com](mailto:info@advancedenzymes.com), [www.advancedenzymes.com](http://www.advancedenzymes.com)

Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
Cost of acquisition and/or the price at which the shares are acquired	Total investment upto ₹10 million
Percentage of shareholding / control acquired and / or number of shares	JC Biotech Private Limited (Subsidiary) to invest in 26% Equity stake in the Target entity
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Brief background: As mentioned above. Target entity presence: India Revenue and Profit After Tax ("PAT") for last three Financial Years - Not Applicable as of now as mentioned above. Post completion of investment in 26% stake by the said Subsidiary, the said Target Entity will become associate company of the said Subsidiary.